Pfizer Breast-Cancer Study Meets Primary Endpoint

Pfizer said a late-stage study of its Ibrance breast-cancer drug in combination with fulvestrant was stopped early after meeting its primary endpoint of demonstrating improvement in progression-free survival.



from WSJ.com: US Business http://ift.tt/1DHSEWO

via IFTTT